AVR 0.61% $11.50 anteris technologies ltd

VacuCel Clinical Literature Review, page-6

  1. 3,021 Posts.
    lightbulb Created with Sketch. 1849
    What a great article selling the features and benefits of VascuCel. We are on to a winner here and a no brainer for Surgeons (and patients if they were educated).

    Funnily enough the adoption of VascuCel could well boost awareness for the increased adoption of CardioCel.
 
watchlist Created with Sketch. Add AVR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.